ClinicalTrials.gg
CompletedNCT01977573Updated Oct 12, 2018Results posted

A Study to Evaluate Safety and Efficacy of GSK1278863 in Non-Dialysis Dependent (NDD) Subjects With Anemia Associated With Chronic Kidney Diseases (CKD)

A Phase 2 interventional study of GSK1278863 and rhEPO in Anaemia, sponsored by GlaxoSmithKline. Completed at 123 sites in 15 countries. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2018-10-12.

Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
252
Allocation
Randomized
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 30 studies testing GSK1278863 in Anemia — 1 open to participants now, 1 under way, 1 of them phase 3. GSK1278863 · Anemia.

Enrollment
8th of 30
252 · median 76
Started
2013
with 2 others
Phase 2
10 of 30
none open now
Registered
6th of 30
by date
Lead sponsor
28 of 30
GlaxoSmithKline

Among the 30 studies testing GSK1278863 in Anemia, this one is the 8th largest by enrollment, is one of 3 that started in 2013, is one of 10 in phase 2, and was the 6th registered.

Anemia

1,810 studies on the registry are indexed under Anemia; 215 are open to participants now.

Browse Anemia studies →

Open to participants now

1 of the 30 studies testing GSK1278863 in Anemia is open now. Recruiting first, the newest first:

About GSK1278863

GSK1278863: first FDA approval 2023 (JESDUVROQ). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 122 Anemia studies recruiting now, 67 (55%) set no upper age limit and 37 (30%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies testing GSK1278863 in Anemia, or all of them as a file.
02

Study summary

This study will be conducted in approximately 228 subjects with anemia associated with CKD who are not on dialysis. Two groups of subjects will be enrolled into the study: Group 1: recombinant human erythropoietin (rhEPO) naive subjects; Group 2: rhEPO users, who are currently receiving rhEPO. Subjects who are rhEPO naive will be randomized to receive either GSK1278863 once daily (QD) or rhEPO in a 3:1 fashion; subjects who are receiving an rhEPO before enrolling (rhEPO users) will be randomized in a 1:1 fashion to GSK1278863 QD or to the control arm. For those randomized to the control arm, the decision around whether the subject requires rhEPO, the selection of the type of rhEPO (if needed) and the choice of rhEPO dose to achieve and maintain Hgb concentrations within the target range should be based on Investigator clinical judgment, with the historical rhEPO dose and the current Hgb value being considered. The study consists of a screening phase of at least 4 weeks, a 24-week treatment phase and a follow-up visit that will occur approximately 4 weeks after completing treatment. It is anticipated that the data generated will enable selection of the starting dose(s) and optimize dose adjustment regimen(s) for Phase 3 clinical trials.

03

Conditions studied

  • Anaemia

Keywords

  • Prolyl hydroxylase inhibitor
  • pharmacokinetics
  • GSK1278863
  • Anemia
  • hemoglobin
  • erythropoiesis stimulating agents
  • Chronic kidney disease
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age: >=18 years of age. (Week -4 verification only)
  • Gender: Female and male subjects. (Week -4 verification only) Females: If of , must agree to use one of the approved methods, from Screening until completion of the Follow-up Visit OR Of non-childbearing potential defined as pre-menopausal females with a documented tubal ligation, hysterectomy, or oophorectomy; or defined as 12 months of spontaneous amenorrhea. Females on hormone replacement therapy (HRT) whose menopausal status is in doubt will be required to use one of the approved contraception methods if they wish to continue their HRT during the study. Otherwise they must discontinue HRT to allow confirmation of post-menopausal status prior to study enrolment.
  • interval (QTc): Bazett's Correction of QT Interval (QTcB) \<470 milliseconds (msec) or QTcB \<480 msec in subjects with bundle branch block. There is no QTc criterion for subjects with a predominantly paced rhythm.
  • CKD stage: Kidney Disease Outcomes Quality Initiative (KDOQI) CKD stages 3/4/5 defined by electronic estimated (eGFR) using the CKD Epidemiology Collaboration (CKD-EPI) formula.
  • : Group 1 (rhEPO naïve): Baseline Hgb of 8.0-11.0 g/dL (inclusive) (USA sites only: 8.0-10.0 g/dL, inclusive); Group 2 (rhEPO users): Baseline Hgb of 9.0-11.5 g/dL (inclusive) (USA sites only: 9.0-10.5, inclusive).
  • Stable rhEPO dose for rhEPO users: Group 2 subjects must be using the same rhEPO (epoetins or their biosimilars, or darbepoetin) with total weekly doses that varied by no more than 50% during the 4 weeks prior to Week -4. At Day 1 (randomization), confirm that total weekly doses varied by no more than 50% during the screening period.
  • Oral iron therapy: If on oral iron, then doses must not be changed for the 4 weeks prior to Week -4, during the screening phase, and through the first 4 weeks after Randomization.

Exclusion criteria

Exclusion Criteria:

  • Dialysis: On dialysis or planning to initiate dialysis during the study.
  • Renal transplant: Pre-emptive or scheduled renal transplant.
  • High rhEPO dose: An epoetin dose of >=360 IU/kg/week intravenous (IV) or >=250 IU/kg/week subcutaneous (SC) or darbepoetin dose of >=1.8 microgram per kilogram per week (mcg/kg/week) IV or SC within the prior 8 weeks through Day 1 (randomization).
  • Use of methoxy polyethylene glycol epoetin beta within the prior 8 weeks through Day 1 (randomization).
  • IV iron therapy: Use of IV iron for 4 weeks prior to Screening Week -4, during the screening phase, and through the first 4 weeks after Randomization
  • Vitamin B12: Below the lower limit of the reference range (may rescreen in a minimum of 8 weeks).
  • Folate: \<2.0 nanogram per millilitre (ng/mL) (\<4.5 nanomoles per liter [nmol/L]) (may rescreen in a minimum of 4 weeks).
  • Ferritin: \<40 ng/mL (\<40 mcg/L).
  • Transferrin saturation (TSAT): Below the lower limit of the reference range
  • Myocardial infarction or acute coronary syndrome: Within the 8 weeks prior to Screening through Day 1 (randomization).
  • Stroke or : Within the 8 weeks prior to Week -4 Screening through Day 1 (randomization).
  • Heart failure: Class III/IV heart failure as defined by the (NYHA) functional classification system diagnosed prior to Week -4 Screening through Day 1 (randomization), symptomatic right heart failure diagnosed prior to Week -4 Screening through Day 1 (randomization).
  • Uncontrolled hypertension: Defined as diastolic blood pressure (DBP) >100 mmHg or systolic blood pressure (SBP) >170 mmHg at Week -4 and reconfirmed at Day 1.
  • Thrombotic Disease: History of thrombotic disease (e.g., venous thrombosis such as deep vein thrombosis or pulmonary embolism, or arterial thrombosis such as new onset or worsening limb ischemia requiring intervention), except vascular access thrombosis within the 8 weeks prior to Week -4 Screening through Day 1 (randomization).
  • Ophthalmology disease: Meeting any ophthalmologic-related exclusion criteria determined at the Screening ophthalmology exam.
  • Inflammatory disease: Active chronic inflammatory disease that could impact erythropoiesis (e.g., scleroderma, systemic lupus erythematosis, rheumatoid arthritis, celiac disease) diagnosed prior to Week -4 Screening through Day 1 (randomization).
  • Hematological disease: Any hematological disease including those affecting , white or red blood cells (e.g. sickle cell anemia, myelodysplastic syndromes, hematological , myeloma, hemolytic anemia and thalassemia), coagulation disorders (e.g., antiphospholipid syndrome, Protein C or S deficiency), or any other cause of anemia other than renal disease diagnosed prior to Week -4 Screening through Day 1 (randomization).
  • Liver disease: Current liver disease, known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones) or evidence at Screening of abnormal liver function tests [ (ALT) or aspartate transaminase (AST) >2.0 x (ULN) or total >1.5 x ULN]; or other hepatic abnormalities that in the opinion of the investigator would preclude the subject from participation in the study.
  • Major surgery: Major surgery (excluding vascular access surgery) within the prior 8 weeks, during the Week -4 Screening phase or planned during the study.
  • Transfusion: Blood transfusion within the prior 8 weeks, during the Week -4 Screening phase or an anticipated need for blood transfusion during the study.
  • Gastrointestinal (GI) Bleeding: Evidence of actively bleeding peptic, duodenal, or esophageal ulcer disease OR GI bleeding within the 8 weeks prior to Week -4 Screening through Day 1 (randomization).
  • Acute infection: Clinical evidence of acute infection or history of infection requiring IV antibiotic therapy within the 8 weeks prior to Week -4 Screening through Day 1 (randomization).
  • Malignancy: Subjects with a history of malignancy within the prior 5 years, who receiving treatment for cancer, or who have a strong family history of cancer (e.g., familial cancer disorders); with the exception of squamous cell or basal cell carcinoma of the skin that has been definitively treated prior to Week -4 Screening through Day 1 (randomization).
  • Severe allergic reactions: History of severe allergic or anaphylactic reactions or to in the product (see GSK1278863 IB for list of excipients and rhEPO (refer to local product labelling for details).
  • Drugs and supplements: Use of any prescription or non-prescription drugs or dietary supplements that are prohibited from Week -4 Screening until the Follow-up Visit.
  • Prior investigational product exposure: The Subject has participated in a clinical trial and has received an experimental investigational product within the prior 30 days from Week -4 Screening through Day 1 (randomization).
  • Other Conditions: Any other condition, clinical or laboratory abnormality, or examination finding that the Investigator considers would put the subject at unacceptable risk.
  • Patient participation: Unwillingness or inability of the subject to follow the procedures or lifestyle or dietary restrictions outlined in the protocol.
  • Pregnancy or Lactation: Pregnant females as determined by positive urine human chorionic gonadotropin (hCG) test OR women who are lactating at Week -4 Screening or during the trial.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
252 participants (actual)

Study arms

  • Experimental
    GSK1278863

    Subjects will be administered GSK1278863 QD. Starting dose will be based on data from previous studies with GSK1278863 and dose-response modelling, as well as Baseline Hgb concentration. After 4 Week of fixed dose period, dose may be adjusted to achieve Hgb 9.0 to 10.5 g/dL

    Drug: GSK1278863

  • Other
    Control

    All subjects who are randomized to the Control arm will receive rhEPO (epoetins or their biosimilars, or darbepoetin) as necessary per standard of care, to maintain Hgb levels within the target range. The decision around whether a subject requires rhEPO, selection of the type of rhEPO and rhEPO dose should be based on Investigator clinical judgment, with the historical rhEPO dose (where applicable) and the current Hgb value being considered.

    Drug: rhEPO

Interventions

  • Film-coated tablets containing 0.5 mg, 1 mg, 2 mg, 5mg or matching placebo

  • DrugrhEPO

    Locally sourced rhEPO. All subjects who are randomized to the Control arm will receive rhEPO (epoetins or their biosimilars, or darbepoetin) as necessary per standard of care, to maintain Hgb levels within the target range. The decision around whether a subject requires rhEPO, selection of the type of rhEPO and rhEPO dose should be based on Investigator clinical judgment, with the historical rhEPO dose (where applicable) and the current Hgb value being considered..

06

What researchers measure

Primary outcomes

  1. Summary of Hemoglobin (Hgb) Concentration at Week 24

    The original Hgb Criteria for Group 1- rhEPO naive participants with a stable baseline Hgb of 8.0-10.0 g/dL (8.0-10.0 g/dL USA site only) and for Group 2- rhEPO users with a stable baseline Hgb of 9.0-10.5 g/dL (9.0-10.5 g/dL USA site only); the Hgb target range was 9.0 to 10.5 g/dL (9.0-10.5 g/dL USA site only). The study amended Hgb Criteria for Group 1- rhEPO naive participants with a stable baseline Hgb of 8.0-11.0 g/dL and Group 2- rhEPO users with a stable baseline Hgb of 9.0-11.5 g/dL; Hgb target range - 10.0 to 11.5 g/dL. Data are presented for those participants following the original criteria ("Original") and those following the amended ("Amended") criteria. The primary objective was to characterize the ability of GSK1278863 to achieve mean Hgb response within the target range.

    Time frame: Week 24

Secondary outcomes

  1. Number of Participants With Hemoglobin (Hgb) in the Target Range at Week 24

    Target range is defined as: Original Hgb Criteria of 9.0 to 10.5 gram/deciliter (g/dL), and Amended Hgb Criteria of 10.0 to 11.5 g/dL. Sites in the USA used 9.0 to 10.5 g/dL.

    Time frame: Week 24

  2. Number of Participants Reaching Pre-defined Hgb Stopping Criteria

    The Hgb stopping criteria was a value of \<7.5 mg/dL obtained on-site via a validated point-of-care Hgb measurement device, which necessitated permanent discontinuation of the study medication. None of the participants met the stopping criteria therefore there is no data to present for this outcome measure.

    Time frame: Over a period of 24 Weeks

  3. Percent Change From Baseline in Hepcidin Concentration at Week 24

    Baseline is the last pre-dose hepcidin value. Percent change was calculated as 100 multiplied by (exponential of mean change on log scale minus 1). Change was calculated by subtracting the Baseline value from the Week 24 value.

    Time frame: Baseline and Week 24

  4. Maximum Observed Change From Baseline in Serum Erythropoietin (EPO)

    Blood samples for control arm were collected pre-dose for EPO measurement. Blood samples for GSK1278863 arms were collected on Day 1 (pre-dose ), Week 4 (6-12 hours post-dose ), Week 4 (7-13, 8-14, 9-15, hours post-dose ), Week 8 (pre -dose ), Week 12 (pre -dose ), Week 16 (pre -dose ), Week 20 (pre -dose , 3 hour post-dose ) Week 24 (pre -dose ), and Week 28 (pre -dose ) for EPO measurement. The maximum observed change from baseline in EPO was recorded for each arm. Baseline value for EPO is the pre-dose value on Day 1. Change from Baseline in EPO was calculated as the individual post-baseline values minus the Baseline value.

    Time frame: Baseline to Week 24

  5. Maximum Observed Percent Change From Baseline in Vascular Endothelial Growth Factor (VEGF)

    Blood samples for control arm were collected pre-dose for VEGF measurement. Blood samples for GSK1278863 arms were collected on Day 1 (pre-dose ), Week 4 (6-12 hours post-dose ), Week 4 (7-13, 8-14, 9-15, hours post-dose ), Week 8 (pre -dose ), Week 12 (pre -dose ), Week 16 (pre -dose ), Week 20 (pre -dose , 3 hour post-dose ) Week 24 (pre -dose ), and Week 28 (pre -dose ) for VEGF measurement. The maximum observed change from baseline in VEGF was recorded for each arm . Baseline value for VEGF is the pre-dose value on Day 1. Change from Baseline in VEGF was calculated as the individual post-baseline values minus the Baseline value.

    Time frame: Baseline and up to Week 24

  6. Percentage of Time Within, Below, and Above Hemoglobin (Hgb) Target Range, Between Weeks 12 and 24

    The number of days a participant's Hgb was within target range was calculated by estimating (using linear interpolation) the number of days within target range between two scheduled Hgb visits. Percentage of time within range for a participant was calculated by dividing the total number of days that Hgb was within range during Weeks 12 to 24 by the total number of days the participant remained on treatment during Weeks 12 to 24. Similary, percent of time above and below Hgb target range was calculated. Target range was defined as: Original Hgb Criteria of 9.0 to 10.5 g/dL, and Amended Hgb Criteria of 10.0 to 11.5 g/dL. Sites in the USA used 9.0 to 10.5 g/dL.

    Time frame: Weeks 12 to 24

  7. Change From Baseline in Ferritin Concentration at Week 24

    Baseline is the last pre-dose ferritin value. Change was calculated by subtracting the Baseline value from the Week 24 value.

    Time frame: Baseline and Week 24

  8. Change From Baseline in Transferrin Concentration at Week 24

    Baseline is the last pre-dose transferrin value. Change from Baseline in transferrin was calculated by subtracting the Baseline value from the Week 24 value.

    Time frame: Baseline and Week 24

  9. Percent Change From Baseline in Transferrin Saturation at Week 24

    Transferrin saturation is measured as a percentage; it is a ratio of serum iron and total iron-binding capacity. Baseline is the last pre-dose transferrin saturation value. Percent change was calculated as 100 multiplied by (exponential of mean change on log scale minus 1). Change was calculated by subtracting the Baseline value from the post-dose value.

    Time frame: Baseline and Week 24

  10. Change From Baseline in Total Iron at Week 24

    Baseline is the last pre-dose total iron value. Change from Baseline was calculated by subtracting the Baseline value from the Week 24 value.

    Time frame: Baseline and Week 24

  11. Change From Baseline in Total Iron Binding Capacity (TIBC) at Week 24

    TIBC measures the blood's capacity to bind iron with transferrin. Baseline is the last pre-dose TIBC value. Change from Baseline in TIBC was calculated by subtracting the Baseline value from the Week 24 value.

    Time frame: Baseline and Week 24

  12. Change From Baseline in Reticulocyte Hemoglobin (CHr) at Week 24

    Reticulocytes are slightly immature red blood cells. Reticulocyte Hgb content is used to differentiate iron deficiency from other causes of anemia. Baseline is the last pre-dose CHr value. Change from Baseline in reticulocyte Hgb was calculated by subtracting the Baseline value from the post-dose value.

    Time frame: Baseline and Week 24

  13. Change From Baseline in Hematocrit at Week 24

    Baseline is the last pre-dose hematocrit value. Change from Baseline was calculated by subtracting the Baseline value from the Week 24 value.

    Time frame: Baseline and Week 24

  14. Change From Baseline in Red Blood Cell Count at Week 24

    Baseline is the last pre-dose red blood cell count. Change from Baseline in red blood cell count was calculated by subtracting the Baseline count from the post-dose count.

    Time frame: Baseline and Week 24

  15. Change From Baseline in Reticulocyte Cell Count at Week 24

    Reticulocyte count is a blood test that measures the percentage of reticulocytes in the blood. Reticulocytes are slightly immature red blood cells. Baseline is the last pre-dose red reticulocyte count. Change from Baseline in reticulocyte cell count was calculated by subtracting the Baseline count from the Week 24 count.

    Time frame: Baseline and Week 24

  16. Concentration of GSK1278863 and Relevant Metabolites as a Population Pharmacokinetic Endpoint

    Blood samples were collected for individual plasma GSK1278863 and metabolite (GSK2391220, GSK2487818, GSK2506102, GSK2531398, GSK2531401, and GSK2531403) concentration measurement on Day 1 (pre-dose), Wk 4 (6-12 hour, 7-13 hour, 8-14 hour, 9-15 hour post-dose), and Wk 20 (pre-dose, 1 hour, 2 hour, 3 hour post-dose). Participants available in each arm at the specified time points have been presented.

    Time frame: Day 1 (pre-dose), Week (Wk) 4 (6-12 hour, 7-13 hour, 8-14 hour, 9-15 hour post-dose), and Wk 20 (pre-dose, 1 hour, 2 hour, 3 hour post-dose)

  17. Mean Number of Dose Adjustments up to 24 Weeks

    After 4 Weeks, the need to adjust the dose of GSK1278863 was evaluated at every scheduled visit, to maintain hemoglobin within the target range. Target range was defined as: Original Hgb Criteria of 9.0 to 10.5 g/dL, and Amended Hgb Criteria of 10.0 to 11.5 g/dL. Sites in the USA used 9.0 to 10.5 g/dL. Dose adjustments were assigned automatically via the interactive voice/web response system.

    Time frame: From Week 4 up to 24 Weeks

  18. Number of Participants With Dose Adjustments up to 24 Weeks, as a Measure of Dose Adjustment Frequency

    After 4 Weeks, the need to adjust the dose of GSK1278863 was evaluated at every scheduled visit, to maintain hemoglobin within the target range. Target range was defined as: Original Hgb Criteria of 9.0 to 10.5 g/dL, and Amended Hgb Criteria of 10.0 to 11.5 g/dL. Sites in the USA used 9.0 to 10.5 g/dL. Dose adjustments were assigned automatically via the interactive voice/web response system. Frequency is presented as the number of participants with dose adjustment(s) once, twice, thrice, four times, or five times.

    Time frame: From week 4 up to 24 weeks

  19. Timing of Dose Adjustments at Weeks 4, 8, 12, 16, and 20

    After 4 Weeks, the need to adjust the dose of GSK1278863 was evaluated at every scheduled visit, to maintain hemoglobin within the target range. Target range was defined as: Original Hgb Criteria of 9.0 to 10.5 g/dL, and Amended Hgb Criteria of 10.0 to 11.5 g/dL. Sites in the USA used 9.0 to 10.5 g/dL. Dose adjustments were assigned automatically via the interactive voice/web response system. The number of participants with an adjustment are presented at the timings at which adjustments were done.

    Time frame: From Week 4 up to Week 20

  20. Mean Total Cumulative Dose of GSK1278863 up to 24 Weeks

    The starting dose was kept constant for the first 4 Weeks after randomization. Later, the need to adjust the dose of GSK1288863 was evaluated at every scheduled visit according to a pre-specified algorithm, to achieve and maintain hemoglobin within the specified target range. Target range was defined as: Original Hgb Criteria of 9.0 to 10.5 g/dL, and Amended Hgb Criteria of 10.0 to 11.5 g/dL. Sites in the USA used 9.0 to 10.5 g/dL.

    Time frame: Up to 24 Weeks

  21. Mean Final Dose of GSK1278863 up to 24 Weeks

    The starting dose was kept constant for the first 4 Weeks after randomization. Later, the need to adjust the dose of GSK1288863 was evaluated at every scheduled visit according to a pre-specified algorithm, to achieve and maintain hemoglobin within the specified target range. Target range was defined as: Original Hgb Criteria of 9.0 to 10.5 g/dL, and Amended Hgb Criteria of 10.0 to 11.5 g/dL. Sites in the USA used 9.0 to 10.5 g/dL.

    Time frame: Up to 24 Weeks

  22. Number of Hemoglobin (Hgb) Excursions

    A Hgb excursion is a series of decreasing or increasing Hgb values differing by \>=1.5 grams per deciliter. Hgb cycle is calculated as two consecutive Hgb excursions in different directions.

    Time frame: Up to 24 Weeks.

  23. Number of Hemoglobin (Hgb) Cycles up to 24 Weeks

    A Hgb cycle is calculated as two consecutive Hgb excursions in different directions. A Hgb excursion is a series of decreasing or increasing Hgb values differing by \>=1.5 grams per deciliter.

    Time frame: Up to 24 Weeks

  24. Number of Dose Cycles up to 24 Weeks

    A dose cycle is a series of three directional dose changes (that is, increase, decrease, increase; or decrease, increase, decrease).

    Time frame: Up to 24 weeks

  25. Number of Participants With at Least One Hemoglobin (Hgb) Excursion up to 24 Weeks.

    A Hgb excursion is a series of decreasing or increasing Hgb values differing by \>=1.5 grams per deciliter.

    Time frame: Up to 24 weeks

  26. Number of Participants With at Least One Hemoglobin (Hgb) Cycle up to 24 Weeks

    A Hgb excursion is a series of decreasing or increasing Hgb values differing by \>=1.5 grams per deciliter. A Hgb cycle is two consecutive Hgb excursions in different directions.

    Time frame: Up to 24 weeks

  27. Number of Participants With at Least One Dose Cycle up to 24 Weeks

    A dose cycle is a series of three directional dose changes (that is, increase, decrease, increase; or decrease, increase, decrease). participants

    Time frame: Up to 24 weeks

  28. Number of Participants Receiving Additional Therapies of Blood Transfusions, Intravenous (IV) Iron or rhEPO at Any Time Post-Baseline

    Participants receiving additional therapies of blood transfusions, intravenous (IV) iron or rhEPO any time Post Baseline were analyzed. RhEPO was not applicable for the control arms since it was a planned therapy in those arms, hence presented as NA. (EudraCT only: A value of 99999 is used where no data is available or NA.)

    Time frame: From Day 1 up to Week 28

  29. Number of Weeks Dose Withheld Because Hemoglobin (Hgb) Exceeded the Upper Limit

    Number of Weeks dose was withheld because hemoglobin exceed the upper limit is presented as the number of participants with withheld dose during the time periods categorized by Weeks.

    Time frame: From Week 4 up to Week 24

07

Results

Posted Jun 6, 2016

Participant flow

Two groups of participants(par.) were enrolled in this study. Group 1 consisted of recombinant human erythropoietin(rhEPO)-naive par. whereas Group 2 consisted of rhEPO users.

Participant flow — Overall Study
MilestonerhEPO-Naive GSK1278863rhEPO-Naive ControlrhEPO-User GSK1278863rhEPO-User Control
Started136443636
Completed116413233
Not completed20343
Withdrew: Adverse event7021
Withdrew: Lost to follow-up1001
Withdrew: Physician decision1000
Withdrew: Protocol violation3100
Withdrew: Reached defined stopping criteria2110
Withdrew: Withdrawal by subject6111

Outcome measures

PrimarySummary of Hemoglobin (Hgb) Concentration at Week 24

The original Hgb Criteria for Group 1- rhEPO naive participants with a stable baseline Hgb of 8.0-10.0 g/dL (8.0-10.0 g/dL USA site only) and for Group 2- rhEPO users with a stable baseline Hgb of 9.0-10.5 g/dL (9.0-10.5 g/dL USA site only); the Hgb target range was 9.0 to 10.5 g/dL (9.0-10.5 g/dL USA site only). The study amended Hgb Criteria for Group 1- rhEPO naive participants with a stable baseline Hgb of 8.0-11.0 g/dL and Group 2- rhEPO users with a stable baseline Hgb of 9.0-11.5 g/dL; Hgb target range - 10.0 to 11.5 g/dL. Data are presented for those participants following the original criteria ("Original") and those following the amended ("Amended") criteria. The primary objective was to characterize the ability of GSK1278863 to achieve mean Hgb response within the target range.

Time frame:
Week 24
Reported as:
Mean · grams per deciliter
Summary of Hemoglobin (Hgb) Concentration at Week 24
grams per deciliterrhEPO-Naive GSK1278863rhEPO-Naive ControlrhEPO-User GSK1278863rhEPO-User Control
Original n=45,15,19,1310.20 ± 0.90610.64 ± 0.66410.03 ± 0.52210.66 ± 0.620
Amended n=61,21,11,1710.96 ± 1.04411.05 ± 1.14410.42 ± 0.82710.86 ± 1.182
SecondaryNumber of Participants With Hemoglobin (Hgb) in the Target Range at Week 24

Target range is defined as: Original Hgb Criteria of 9.0 to 10.5 gram/deciliter (g/dL), and Amended Hgb Criteria of 10.0 to 11.5 g/dL. Sites in the USA used 9.0 to 10.5 g/dL.

Time frame:
Week 24
Reported as:
Number · participants
Number of Participants With Hemoglobin (Hgb) in the Target Range at Week 24
participantsrhEPO-Naive GSK1278863rhEPO-Naive ControlrhEPO-User GSK1278863rhEPO-User Control
Number of Participants With Hemoglobin (Hgb) in the Target Range at Week 2478202219
SecondaryNumber of Participants Reaching Pre-defined Hgb Stopping Criteria

The Hgb stopping criteria was a value of \<7.5 mg/dL obtained on-site via a validated point-of-care Hgb measurement device, which necessitated permanent discontinuation of the study medication. None of the participants met the stopping criteria therefore there is no data to present for this outcome measure.

Time frame:
Over a period of 24 Weeks
Reported as:
Number · Participants
Number of Participants Reaching Pre-defined Hgb Stopping Criteria
ParticipantsrhEPO-Naive GSK1278863rhEPO-Naive ControlrhEPO-User GSK1278863rhEPO-User Control
Number of Participants Reaching Pre-defined Hgb Stopping Criteria0000
SecondaryPercent Change From Baseline in Hepcidin Concentration at Week 24

Baseline is the last pre-dose hepcidin value. Percent change was calculated as 100 multiplied by (exponential of mean change on log scale minus 1). Change was calculated by subtracting the Baseline value from the Week 24 value.

Time frame:
Baseline and Week 24
Reported as:
Geometric mean · percent change in Hepcidin
Percent Change From Baseline in Hepcidin Concentration at Week 24
percent change in HepcidinrhEPO-Naive GSK1278863rhEPO-Naive ControlrhEPO-User GSK1278863rhEPO-User Control
Percent Change From Baseline in Hepcidin Concentration at Week 24-19.27 (-28.10 to -9.36)6.67 (-13.62 to 31.72)-9.87 (-28.59 to 13.76)-17.12 (-33.22 to 2.86)
SecondaryMaximum Observed Change From Baseline in Serum Erythropoietin (EPO)

Blood samples for control arm were collected pre-dose for EPO measurement. Blood samples for GSK1278863 arms were collected on Day 1 (pre-dose ), Week 4 (6-12 hours post-dose ), Week 4 (7-13, 8-14, 9-15, hours post-dose ), Week 8 (pre -dose ), Week 12 (pre -dose ), Week 16 (pre -dose ), Week 20 (pre -dose , 3 hour post-dose ) Week 24 (pre -dose ), and Week 28 (pre -dose ) for EPO measurement. The maximum observed change from baseline in EPO was recorded for each arm. Baseline value for EPO is the pre-dose value on Day 1. Change from Baseline in EPO was calculated as the individual post-baseline values minus the Baseline value.

Time frame:
Baseline to Week 24
Reported as:
Mean · International Units per liter
Maximum Observed Change From Baseline in Serum Erythropoietin (EPO)
International Units per literrhEPO-Naive GSK1278863rhEPO-Naive ControlrhEPO-User GSK1278863rhEPO-User Control
Maximum Observed Change From Baseline in Serum Erythropoietin (EPO)7.27 ± 12.74427.05 ± 94.9993.69 ± 20.55425.85 ± 38.890
SecondaryMaximum Observed Percent Change From Baseline in Vascular Endothelial Growth Factor (VEGF)

Blood samples for control arm were collected pre-dose for VEGF measurement. Blood samples for GSK1278863 arms were collected on Day 1 (pre-dose ), Week 4 (6-12 hours post-dose ), Week 4 (7-13, 8-14, 9-15, hours post-dose ), Week 8 (pre -dose ), Week 12 (pre -dose ), Week 16 (pre -dose ), Week 20 (pre -dose , 3 hour post-dose ) Week 24 (pre -dose ), and Week 28 (pre -dose ) for VEGF measurement. The maximum observed change from baseline in VEGF was recorded for each arm . Baseline value for VEGF is the pre-dose value on Day 1. Change from Baseline in VEGF was calculated as the individual post-baseline values minus the Baseline value.

Time frame:
Baseline and up to Week 24
Reported as:
Geometric mean · percent change in VEGF concentration
Maximum Observed Percent Change From Baseline in Vascular Endothelial Growth Factor (VEGF)
percent change in VEGF concentrationrhEPO-Naive GSK1278863rhEPO-Naive ControlrhEPO-User GSK1278863rhEPO-User Control
Maximum Observed Percent Change From Baseline in Vascular Endothelial Growth Factor (VEGF)76.36 (59.46 to 95.06)26.84 (1.73 to 58.15)49.99 (28.28 to 75.39)40.85 (19.14 to 66.52)
SecondaryPercentage of Time Within, Below, and Above Hemoglobin (Hgb) Target Range, Between Weeks 12 and 24

The number of days a participant's Hgb was within target range was calculated by estimating (using linear interpolation) the number of days within target range between two scheduled Hgb visits. Percentage of time within range for a participant was calculated by dividing the total number of days that Hgb was within range during Weeks 12 to 24 by the total number of days the participant remained on treatment during Weeks 12 to 24. Similary, percent of time above and below Hgb target range was calculated. Target range was defined as: Original Hgb Criteria of 9.0 to 10.5 g/dL, and Amended Hgb Criteria of 10.0 to 11.5 g/dL. Sites in the USA used 9.0 to 10.5 g/dL.

Time frame:
Weeks 12 to 24
Reported as:
Mean · percentage of days
Percentage of Time Within, Below, and Above Hemoglobin (Hgb) Target Range, Between Weeks 12 and 24
percentage of daysrhEPO-Naive GSK1278863rhEPO-Naive ControlrhEPO-User GSK1278863rhEPO-User Control
Percentage of time within target range68.99 ± 34.61251.01 ± 41.40375.06 ± 32.48561.29 ± 43.352
Percentage of time above target range22.84 ± 33.82545.10 ± 42.57917.96 ± 28.80931.10 ± 41.683
Percentage of time below target range8.17 ± 20.3013.89 ± 16.1756.98 ± 21.1187.61 ± 25.113
SecondaryChange From Baseline in Ferritin Concentration at Week 24

Baseline is the last pre-dose ferritin value. Change was calculated by subtracting the Baseline value from the Week 24 value.

Time frame:
Baseline and Week 24
Reported as:
Mean · micrograms per liter
Change From Baseline in Ferritin Concentration at Week 24
micrograms per literrhEPO-Naive GSK1278863rhEPO-Naive ControlrhEPO-User GSK1278863rhEPO-User Control
Change From Baseline in Ferritin Concentration at Week 24-30.8 ± 110.50-2.4 ± 77.06-63.4 ± 141.93-20.4 ± 63.38
SecondaryChange From Baseline in Transferrin Concentration at Week 24

Baseline is the last pre-dose transferrin value. Change from Baseline in transferrin was calculated by subtracting the Baseline value from the Week 24 value.

Time frame:
Baseline and Week 24
Reported as:
Mean · grams per liter
Change From Baseline in Transferrin Concentration at Week 24
grams per literrhEPO-Naive GSK1278863rhEPO-Naive ControlrhEPO-User GSK1278863rhEPO-User Control
Change From Baseline in Transferrin Concentration at Week 240.077 ± 0.3577-0.008 ± 0.26940.171 ± 0.41240.018 ± 0.2395
SecondaryPercent Change From Baseline in Transferrin Saturation at Week 24

Transferrin saturation is measured as a percentage; it is a ratio of serum iron and total iron-binding capacity. Baseline is the last pre-dose transferrin saturation value. Percent change was calculated as 100 multiplied by (exponential of mean change on log scale minus 1). Change was calculated by subtracting the Baseline value from the post-dose value.

Time frame:
Baseline and Week 24
Reported as:
Geometric mean · percent change
Percent Change From Baseline in Transferrin Saturation at Week 24
percent changerhEPO-Naive GSK1278863rhEPO-Naive ControlrhEPO-User GSK1278863rhEPO-User Control
Percent Change From Baseline in Transferrin Saturation at Week 24-1.1 (-8.0 to 6.4)12.3 (2.2 to 23.3)-15.7 (-26.8 to -3.0)11.4 (-14.7 to 45.6)
SecondaryChange From Baseline in Total Iron at Week 24

Baseline is the last pre-dose total iron value. Change from Baseline was calculated by subtracting the Baseline value from the Week 24 value.

Time frame:
Baseline and Week 24
Reported as:
Mean · micromoles per liter
Change From Baseline in Total Iron at Week 24
micromoles per literrhEPO-Naive GSK1278863rhEPO-Naive ControlrhEPO-User GSK1278863rhEPO-User Control
Change From Baseline in Total Iron at Week 241.0 ± 5.012.5 ± 5.98-1.8 ± 5.540.7 ± 8.36
SecondaryChange From Baseline in Total Iron Binding Capacity (TIBC) at Week 24

TIBC measures the blood's capacity to bind iron with transferrin. Baseline is the last pre-dose TIBC value. Change from Baseline in TIBC was calculated by subtracting the Baseline value from the Week 24 value.

Time frame:
Baseline and Week 24
Reported as:
Mean · micromoles per liter
Change From Baseline in Total Iron Binding Capacity (TIBC) at Week 24
micromoles per literrhEPO-Naive GSK1278863rhEPO-Naive ControlrhEPO-User GSK1278863rhEPO-User Control
Change From Baseline in Total Iron Binding Capacity (TIBC) at Week 243.2 ± 6.460.1 ± 5.173.0 ± 9.44-1.0 ± 6.69
SecondaryChange From Baseline in Reticulocyte Hemoglobin (CHr) at Week 24

Reticulocytes are slightly immature red blood cells. Reticulocyte Hgb content is used to differentiate iron deficiency from other causes of anemia. Baseline is the last pre-dose CHr value. Change from Baseline in reticulocyte Hgb was calculated by subtracting the Baseline value from the post-dose value.

Time frame:
Baseline and Week 24
Reported as:
Mean · picogram
Change From Baseline in Reticulocyte Hemoglobin (CHr) at Week 24
picogramrhEPO-Naive GSK1278863rhEPO-Naive ControlrhEPO-User GSK1278863rhEPO-User Control
Change From Baseline in Reticulocyte Hemoglobin (CHr) at Week 24-0.19 ± 1.109-0.33 ± 1.085-0.32 ± 0.864-0.19 ± 1.546
SecondaryChange From Baseline in Hematocrit at Week 24

Baseline is the last pre-dose hematocrit value. Change from Baseline was calculated by subtracting the Baseline value from the Week 24 value.

Time frame:
Baseline and Week 24
Reported as:
Mean · percentage change in Fraction of 1
Change From Baseline in Hematocrit at Week 24
percentage change in Fraction of 1rhEPO-Naive GSK1278863rhEPO-Naive ControlrhEPO-User GSK1278863rhEPO-User Control
Change From Baseline in Hematocrit at Week 242.64 ± 3.3893.13 ± 3.245-0.66 ± 3.0742.09 ± 3.243
SecondaryChange From Baseline in Red Blood Cell Count at Week 24

Baseline is the last pre-dose red blood cell count. Change from Baseline in red blood cell count was calculated by subtracting the Baseline count from the post-dose count.

Time frame:
Baseline and Week 24
Reported as:
Mean · 10^12 cells per liter
Change From Baseline in Red Blood Cell Count at Week 24
10^12 cells per literrhEPO-Naive GSK1278863rhEPO-Naive ControlrhEPO-User GSK1278863rhEPO-User Control
Change From Baseline in Red Blood Cell Count at Week 240.28 ± 0.3770.34 ± 0.365-0.08 ± 0.3120.22 ± 0.318
SecondaryChange From Baseline in Reticulocyte Cell Count at Week 24

Reticulocyte count is a blood test that measures the percentage of reticulocytes in the blood. Reticulocytes are slightly immature red blood cells. Baseline is the last pre-dose red reticulocyte count. Change from Baseline in reticulocyte cell count was calculated by subtracting the Baseline count from the Week 24 count.

Time frame:
Baseline and Week 24
Reported as:
Mean · percentage of reticulocytes
Change From Baseline in Reticulocyte Cell Count at Week 24
percentage of reticulocytesrhEPO-Naive GSK1278863rhEPO-Naive ControlrhEPO-User GSK1278863rhEPO-User Control
Change From Baseline in Reticulocyte Cell Count at Week 24-0.02 ± 0.551-0.12 ± 0.6480.27 ± 0.892-0.09 ± 0.755
SecondaryConcentration of GSK1278863 and Relevant Metabolites as a Population Pharmacokinetic Endpoint

Blood samples were collected for individual plasma GSK1278863 and metabolite (GSK2391220, GSK2487818, GSK2506102, GSK2531398, GSK2531401, and GSK2531403) concentration measurement on Day 1 (pre-dose), Wk 4 (6-12 hour, 7-13 hour, 8-14 hour, 9-15 hour post-dose), and Wk 20 (pre-dose, 1 hour, 2 hour, 3 hour post-dose). Participants available in each arm at the specified time points have been presented.

Time frame:
Day 1 (pre-dose), Week (Wk) 4 (6-12 hour, 7-13 hour, 8-14 hour, 9-15 hour post-dose), and Wk 20 (pre-dose, 1 hour, 2 hour, 3 hour post-dose)
Reported as:
Mean · nanograms per milliliter
Concentration of GSK1278863 and Relevant Metabolites as a Population Pharmacokinetic Endpoint
nanograms per milliliterrhEPO-Naive GSK1278863rhEPO-User GSK1278863
GSK1278863, Day 1, Pre-Dose, n=128, 350.0 ± 0.000.0 ± 0.00
GSK1278863, Wk 4, 6-12 hour Post-Dose, n=116, 312.0 ± 5.181.1 ± 1.69
GSK1278863, Wk 4, 7-13 hour Post-Dose, n=117, 312.3 ± 7.060.8 ± 1.22
GSK1278863, Wk 4, 8-14 hour Post-Dose, n=116, 311.6 ± 4.931.6 ± 5.49
GSK1278863, Wk 4, 9-15 hour Post-Dose, n=116, 311.4 ± 4.521.6 ± 4.60
GSK1278863, Wk 20, Pre-Dose, n=111, 290.6 ± 3.070.3 ± 0.92
GSK1278863, Wk 20, 1 hour Post-Dose, n=110, 2822.8 ± 35.9319.8 ± 19.66
GSK1278863, Wk 20, 2 hour Post-Dose, n=109, 2917.0 ± 28.5719.4 ± 21.92
GSK1278863, Wk 20, 3 hour Post-Dose, n=109, 2911.6 ± 19.5613.9 ± 19.12
GSK2391220, Day 1, Pre-Dose, n=128, 350.0 ± 0.000.0 ± 0.00
GSK2391220, Wk 4, 6-12 hour Post-Dose, n=116, 313.2 ± 5.213.7 ± 2.89
GSK2391220, Wk 4, 7-13 hour Post-Dose, n=117, 313.1 ± 5.673.2 ± 2.43
GSK2391220, Wk 4, 8-14 hour Post-Dose, n=116, 312.8 ± 5.012.9 ± 2.54
GSK2391220, Wk 4, 9-15 hour Post-Dose, n=116, 312.6 ± 4.893.1 ± 2.76
GSK2391220, Wk 20, Pre-Dose, n=111, 291.0 ± 2.060.8 ± 0.98
GSK2391220, Wk 20, 1 hour Post-Dose, n=110, 282.1 ± 3.521.6 ± 1.39
GSK2391220, Wk 20, 2 hour Post-Dose, n=109, 293.8 ± 5.083.7 ± 2.98
GSK2391220, Wk 20, 3 hour Post-Dose, n=109, 294.5 ± 5.434.7 ± 3.53
GSK2487818, Day 1, Pre-Dose, n=128, 350.0 ± 0.000.0 ± 0.00
GSK2487818, Wk 4, 6-12 hour Post-Dose, n=116, 311.2 ± 3.871.0 ± 0.96
GSK2487818, Wk 4, 7-13 hour Post-Dose, n=116, 311.1 ± 4.110.7 ± 0.70
GSK2487818, Wk 4, 8-14 hour Post-Dose, n=116, 311.0 ± 4.480.6 ± 0.66
GSK2487818, Wk 4, 9-15 hour Post-Dose, n=116, 310.9 ± 4.090.8 ± 1.16
GSK2487818, Wk 20, Pre-Dose, n=111, 290.2 ± 0.560.1 ± 0.31
GSK2487818, Wk 20, 1 hour Post-Dose, n=110, 281.4 ± 3.071.0 ± 1.09
GSK2487818, Wk 20, 2 hour Post-Dose, n=109, 292.8 ± 4.282.7 ± 2.21
GSK2487818, Wk 20, 3 hour Post-Dose, n=109, 293.1 ± 4.073.1 ± 2.56
GSK2506102, Day 1, Pre-Dose, n=128, 350.0 ± 0.000.0 ± 0.00
GSK2506102, Wk 4, 6-12 hour Post-Dose, n=116, 311.0 ± 1.301.2 ± 0.65
GSK2506102, Wk 4, 7-13 hour Post-Dose, n=117, 311.0 ± 1.511.1 ± 0.61
GSK2506102, Wk 4, 8-14 hour Post-Dose, n=116, 310.9 ± 1.191.0 ± 0.61
GSK2506102, Wk 4, 9-15 hour Post-Dose, n=116, 310.9 ± 1.291.1 ± 0.69
GSK2506102, Wk 20, Pre-Dose, n=111, 290.4 ± 0.730.4 ± 0.42
GSK2506102, Wk 20, 1 hour Post-Dose, n=110, 280.6 ± 0.880.5 ± 0.40
GSK2506102, Wk 20, 2 hour Post-Dose, n=109, 290.9 ± 1.151.0 ± 0.71
GSK2506102, Wk 20, 3 hour Post-Dose, n=109, 291.1 ± 1.251.2 ± 0.88
GSK2531398, Day 1, Pre-Dose, n=128, 350.0 ± 0.010.0 ± 0.00
GSK2531398, Wk 4, 6-12 hour Post-Dose, n=116, 311.3 ± 2.061.4 ± 1.08
GSK2531398, Wk 4, 7-13 hour Post-Dose, n=117, 311.2 ± 2.501.2 ± 0.99
GSK2531398, Wk 4, 8-14 hour Post-Dose, n=116, 311.1 ± 2.011.1 ± 0.93
GSK2531398, Wk 4, 9-15 hour Post-Dose, n=116, 311.0 ± 2.101.2 ± 1.12
GSK2531398, Wk 20, Pre-Dose, n=111, 290.3 ± 0.870.3 ± 0.38
GSK2531398, Wk 20, 1 hour Post-Dose, n=110, 280.8 ± 1.530.6 ± 0.54
GSK2531398, Wk 20, 2 hour Post-Dose, n=109, 291.6 ± 2.311.5 ± 1.22
GSK2531398, Wk 20, 3 hour Post-Dose, n=109, 292.0 ± 2.422.0 ± 1.57
GSK2531401, Day 1, Pre-Dose, n=128, 350.0 ± 0.000.0 ± 0.00
GSK2531401, Wk 4, 6-12 hour Post-Dose, n=116, 312.8 ± 4.004.3 ± 2.55
GSK2531401, Wk 4, 7-13 hour Post-Dose, n=117, 312.7 ± 3.584.0 ± 2.29
GSK2531401, Wk 4, 8-14 hour Post-Dose, n=116, 312.7 ± 3.743.8 ± 2.31
GSK2531401, Wk 4, 9-15 hour Post-Dose, n=116, 312.5 ± 3.533.8 ± 2.29
GSK2531401, Wk 20, Pre-Dose, n=111, 291.3 ± 2.411.4 ± 1.38
GSK2531401, Wk 20, 1 hour Post-Dose, n=110, 281.6 ± 2.651.6 ± 1.29
GSK2531401, Wk 20, 2 hour Post-Dose, n=109, 292.3 ± 3.142.5 ± 1.85
GSK2531401, Wk 20, 3 hour Post-Dose, n=109, 292.8 ± 3.503.2 ± 2.22
GSK2531403, Day 1, Pre-Dose, n=128, 350.0 ± 0.000.0 ± 0.00
GSK2531403, Wk 4, 6-12 hour Post-Dose, n=116, 313.7 ± 5.434.5 ± 3.14
GSK2531403, Wk 4, 7-13 hour Post-Dose, n=117, 313.5 ± 5.273.9 ± 2.56
GSK2531403, Wk 4, 8-14 hour Post-Dose, n=116, 313.4 ± 5.683.7 ± 2.72
GSK2531403, Wk 4, 9-15 hour Post-Dose, n=116, 313.2 ± 5.423.8 ± 3.01
GSK2531403, Wk 20, Pre-Dose, n=111, 291.4 ± 2.651.2 ± 1.25
GSK2531403, Wk 20, 1 hour Post-Dose, n=110, 282.3 ± 3.691.9 ± 1.38
GSK2531403, Wk 20, 2 hour Post-Dose, n=109, 293.9 ± 5.033.8 ± 2.95
GSK2531403, Wk 20, 3 hour Post-Dose, n=109, 294.7 ± 5.434.9 ± 3.75
SecondaryMean Number of Dose Adjustments up to 24 Weeks

After 4 Weeks, the need to adjust the dose of GSK1278863 was evaluated at every scheduled visit, to maintain hemoglobin within the target range. Target range was defined as: Original Hgb Criteria of 9.0 to 10.5 g/dL, and Amended Hgb Criteria of 10.0 to 11.5 g/dL. Sites in the USA used 9.0 to 10.5 g/dL. Dose adjustments were assigned automatically via the interactive voice/web response system.

Time frame:
From Week 4 up to 24 Weeks
Reported as:
Mean · number of adjustments
Mean Number of Dose Adjustments up to 24 Weeks
number of adjustmentsrhEPO-Naive GSK1278863rhEPO-User GSK1278863
Mean Number of Dose Adjustments up to 24 Weeks1.8 ± 0.821.7 ± 0.72
SecondaryNumber of Participants With Dose Adjustments up to 24 Weeks, as a Measure of Dose Adjustment Frequency

After 4 Weeks, the need to adjust the dose of GSK1278863 was evaluated at every scheduled visit, to maintain hemoglobin within the target range. Target range was defined as: Original Hgb Criteria of 9.0 to 10.5 g/dL, and Amended Hgb Criteria of 10.0 to 11.5 g/dL. Sites in the USA used 9.0 to 10.5 g/dL. Dose adjustments were assigned automatically via the interactive voice/web response system. Frequency is presented as the number of participants with dose adjustment(s) once, twice, thrice, four times, or five times.

Time frame:
From week 4 up to 24 weeks
Reported as:
Number · participants
Number of Participants With Dose Adjustments up to 24 Weeks, as a Measure of Dose Adjustment Frequency
participantsrhEPO-Naive GSK1278863rhEPO-User GSK1278863
Once3911
Twice5011
Thrice84
Four times40
Five times or more10
SecondaryTiming of Dose Adjustments at Weeks 4, 8, 12, 16, and 20

After 4 Weeks, the need to adjust the dose of GSK1278863 was evaluated at every scheduled visit, to maintain hemoglobin within the target range. Target range was defined as: Original Hgb Criteria of 9.0 to 10.5 g/dL, and Amended Hgb Criteria of 10.0 to 11.5 g/dL. Sites in the USA used 9.0 to 10.5 g/dL. Dose adjustments were assigned automatically via the interactive voice/web response system. The number of participants with an adjustment are presented at the timings at which adjustments were done.

Time frame:
From Week 4 up to Week 20
Reported as:
Number · Participants
Timing of Dose Adjustments at Weeks 4, 8, 12, 16, and 20
ParticipantsrhEPO-Naive GSK1278863rhEPO-User GSK1278863
Week 47821
Week 8246
Week 12307
Week 16306
Week 20225
SecondaryMean Total Cumulative Dose of GSK1278863 up to 24 Weeks

The starting dose was kept constant for the first 4 Weeks after randomization. Later, the need to adjust the dose of GSK1288863 was evaluated at every scheduled visit according to a pre-specified algorithm, to achieve and maintain hemoglobin within the specified target range. Target range was defined as: Original Hgb Criteria of 9.0 to 10.5 g/dL, and Amended Hgb Criteria of 10.0 to 11.5 g/dL. Sites in the USA used 9.0 to 10.5 g/dL.

Time frame:
Up to 24 Weeks
Reported as:
Mean · milligrams
Mean Total Cumulative Dose of GSK1278863 up to 24 Weeks
milligramsrhEPO-Naive GSK1278863rhEPO-User GSK1278863
Mean Total Cumulative Dose of GSK1278863 up to 24 Weeks249.75 ± 186.921320.42 ± 214.865
SecondaryMean Final Dose of GSK1278863 up to 24 Weeks

The starting dose was kept constant for the first 4 Weeks after randomization. Later, the need to adjust the dose of GSK1288863 was evaluated at every scheduled visit according to a pre-specified algorithm, to achieve and maintain hemoglobin within the specified target range. Target range was defined as: Original Hgb Criteria of 9.0 to 10.5 g/dL, and Amended Hgb Criteria of 10.0 to 11.5 g/dL. Sites in the USA used 9.0 to 10.5 g/dL.

Time frame:
Up to 24 Weeks
Reported as:
Mean · milligrams per day
Mean Final Dose of GSK1278863 up to 24 Weeks
milligrams per dayrhEPO-Naive GSK1278863rhEPO-User GSK1278863
Mean Final Dose of GSK1278863 up to 24 Weeks1.75 ± 1.8091.86 ± 1.692
SecondaryNumber of Hemoglobin (Hgb) Excursions

A Hgb excursion is a series of decreasing or increasing Hgb values differing by \>=1.5 grams per deciliter. Hgb cycle is calculated as two consecutive Hgb excursions in different directions.

Time frame:
Up to 24 Weeks.
Reported as:
Number · number of excursions
Number of Hemoglobin (Hgb) Excursions
number of excursionsrhEPO-Naive GSK1278863rhEPO-Naive ControlrhEPO-User GSK1278863rhEPO-User Control
Number of Hemoglobin (Hgb) Excursions261049
SecondaryNumber of Hemoglobin (Hgb) Cycles up to 24 Weeks

A Hgb cycle is calculated as two consecutive Hgb excursions in different directions. A Hgb excursion is a series of decreasing or increasing Hgb values differing by \>=1.5 grams per deciliter.

Time frame:
Up to 24 Weeks
Reported as:
Number · number of Hgb cycles
Number of Hemoglobin (Hgb) Cycles up to 24 Weeks
number of Hgb cyclesrhEPO-Naive GSK1278863rhEPO-Naive ControlrhEPO-User GSK1278863rhEPO-User Control
Number of Hemoglobin (Hgb) Cycles up to 24 Weeks3———
SecondaryNumber of Dose Cycles up to 24 Weeks

A dose cycle is a series of three directional dose changes (that is, increase, decrease, increase; or decrease, increase, decrease).

Time frame:
Up to 24 weeks
Reported as:
Number · number
Number of Dose Cycles up to 24 Weeks
numberrhEPO-Naive GSK1278863rhEPO-User GSK1278863
Number of Dose Cycles up to 24 Weeks1—
SecondaryNumber of Participants With at Least One Hemoglobin (Hgb) Excursion up to 24 Weeks.

A Hgb excursion is a series of decreasing or increasing Hgb values differing by \>=1.5 grams per deciliter.

Time frame:
Up to 24 weeks
Reported as:
Number · participants
Number of Participants With at Least One Hemoglobin (Hgb) Excursion up to 24 Weeks.
participantsrhEPO-Naive GSK1278863rhEPO-Naive ControlrhEPO-User GSK1278863rhEPO-User Control
Number of Participants With at Least One Hemoglobin (Hgb) Excursion up to 24 Weeks.231048
SecondaryNumber of Participants With at Least One Hemoglobin (Hgb) Cycle up to 24 Weeks

A Hgb excursion is a series of decreasing or increasing Hgb values differing by \>=1.5 grams per deciliter. A Hgb cycle is two consecutive Hgb excursions in different directions.

Time frame:
Up to 24 weeks
Reported as:
Number · participants
Number of Participants With at Least One Hemoglobin (Hgb) Cycle up to 24 Weeks
participantsrhEPO-Naive GSK1278863rhEPO-Naive ControlrhEPO-User GSK1278863rhEPO-User Control
Number of Participants With at Least One Hemoglobin (Hgb) Cycle up to 24 Weeks3000
SecondaryNumber of Participants With at Least One Dose Cycle up to 24 Weeks

A dose cycle is a series of three directional dose changes (that is, increase, decrease, increase; or decrease, increase, decrease). participants

Time frame:
Up to 24 weeks
Reported as:
Number · participants
Number of Participants With at Least One Dose Cycle up to 24 Weeks
participantsrhEPO-Naive GSK1278863rhEPO-User GSK1278863
Number of Participants With at Least One Dose Cycle up to 24 Weeks10
SecondaryNumber of Participants Receiving Additional Therapies of Blood Transfusions, Intravenous (IV) Iron or rhEPO at Any Time Post-Baseline

Participants receiving additional therapies of blood transfusions, intravenous (IV) iron or rhEPO any time Post Baseline were analyzed. RhEPO was not applicable for the control arms since it was a planned therapy in those arms, hence presented as NA. (EudraCT only: A value of 99999 is used where no data is available or NA.)

Time frame:
From Day 1 up to Week 28
Reported as:
Number · participants
Number of Participants Receiving Additional Therapies of Blood Transfusions, Intravenous (IV) Iron or rhEPO at Any Time Post-Baseline
participantsrhEPO-Naive GSK1278863rhEPO-Naive ControlrhEPO-User GSK1278863rhEPO-User Control
Blood Transfusions3110
IV Iron20334
Inadvertent rhEPO use4NA9NA
Rescue rhEPO1NA0NA
SecondaryNumber of Weeks Dose Withheld Because Hemoglobin (Hgb) Exceeded the Upper Limit

Number of Weeks dose was withheld because hemoglobin exceed the upper limit is presented as the number of participants with withheld dose during the time periods categorized by Weeks.

Time frame:
From Week 4 up to Week 24
Reported as:
Number · participants
Number of Weeks Dose Withheld Because Hemoglobin (Hgb) Exceeded the Upper Limit
participantsrhEPO-Naive GSK1278863rhEPO-User GSK1278863
0 Weeks10230
>0-4 Weeks42
>4-8 Weeks80
>8-12 Weeks80
>12 Weeks10

Adverse events

Collected over Adverse events (AEs) and serious adverse events (SAEs) were collected from the start of study treatment until the follow-up contact (up to 28 weeks).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
rhEPO-Naive GSK1278863—23/134 (17.2%)47/134 (35.1%)
rhEPO-Naive Control—7/45 (15.6%)14/45 (31.1%)
rhEPO-User GSK1278863—7/36 (19.4%)20/36 (55.6%)
rhEPO-User Control—7/35 (20%)13/35 (37.1%)
Most frequent serious events
Showing 10 of 63
Most frequent serious events
EventrhEPO-Naive GSK1278863rhEPO-Naive ControlrhEPO-User GSK1278863rhEPO-User Control
ANY EVENTRenal and urinary disorders2/1343/452/363/35
ANY EVENTInfections and infestations2/1343/451/361/35
RENAL FAILURE CHRONICRenal and urinary disorders2/1342/451/361/35
ANY EVENTCardiac disorders4/1341/450/361/35
RENAL FAILURERenal and urinary disorders0/1340/450/361/35
RENAL IMPAIRMENTRenal and urinary disorders0/1340/450/361/35
PNEUMONIA PNEUMOCOCCALInfections and infestations0/1340/450/361/35
CARDIAC FAILURE CONGESTIVECardiac disorders1/1340/450/361/35
ANY EVENTGastrointestinal disorders1/1340/451/361/35
RECTAL HAEMORRHAGEGastrointestinal disorders0/1340/450/361/35
Most frequent other events
Showing 10 of 19
Most frequent other events
EventrhEPO-Naive GSK1278863rhEPO-Naive ControlrhEPO-User GSK1278863rhEPO-User Control
NASOPHARYNGITISInfections and infestations15/1342/457/362/35
DIARRHOEAGastrointestinal disorders10/1340/450/366/35
HYPERTENSIONVascular disorders2/1341/454/361/35
PRURITUSSkin and subcutaneous tissue disorders0/1344/450/360/35
BRONCHITISInfections and infestations2/1341/450/363/35
ARTHRALGIAMusculoskeletal and connective tissue disorders2/1342/451/363/35
OEDEMA PERIPHERALGeneral disorders5/1340/452/363/35
AnaemiaBlood and lymphatic system disorders0/1341/453/360/35
AstheniaGeneral disorders1/1343/451/360/35
NAUSEAGastrointestinal disorders8/1341/451/360/35

Baseline characteristics

252 participants were randomized however the Baseline measurements are provided for the Intent-to-Treat (ITT) population (235 participants), which consisted of all randomized participants who received at least one dose of study drug, had a Baseline and at least one corresponding on-treatment assessment.

Age, Continuous
Age, Continuous(Years)rhEPO-Naive GSK1278863rhEPO-Naive ControlrhEPO-User GSK1278863rhEPO-User ControlTotal
Mean67.6 ± 12.2164.3 ± 14.2262.0 ± 14.0666.7 ± 12.8966.1 ± 13.04
Sex: Female, Male
Sex: Female, Male(Participants)rhEPO-Naive GSK1278863rhEPO-Naive ControlrhEPO-User GSK1278863rhEPO-User ControlTotal
Female75231723138
Male4820161397
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)rhEPO-Naive GSK1278863rhEPO-Naive ControlrhEPO-User GSK1278863rhEPO-User ControlTotal
African American/African Heritage1422422
Central/South Asian Heritage00011
Japanese/East Asian/South East Asian Heritage281191260
White81302219152
08

Study locations

123 sites
  • GSK Investigational Site
    Peoria, Arizona 85381, United States
  • GSK Investigational Site
    Azusa, California 91702, United States
  • GSK Investigational Site
    La Mesa, California 91942, United States
  • GSK Investigational Site
    Laguna Hills, California 92653, United States
  • GSK Investigational Site
    Los Angeles, California 90022, United States
  • GSK Investigational Site
    Los Angeles, California 90025, United States
  • GSK Investigational Site
    San Diego, California 92103, United States
  • GSK Investigational Site
    San Dimas, California 91773, United States
  • GSK Investigational Site
    West Hills, California 91307, United States
  • GSK Investigational Site
    Lauderdale Lakes, Florida 33313, United States
  • GSK Investigational Site
    Miami, Florida 33150, United States
  • GSK Investigational Site
    Pembroke Pines, Florida 33028, United States
  • GSK Investigational Site
    Macon, Georgia 31217, United States
  • GSK Investigational Site
    Savannah, Georgia 31406, United States
  • GSK Investigational Site
    Evergreen Park, Illinois 60805, United States
  • GSK Investigational Site
    Shreveport, Louisiana 71101, United States
  • GSK Investigational Site
    Farmington, Missouri 63640, United States
  • GSK Investigational Site
    Charlotte, North Carolina, United States
  • GSK Investigational Site
    Bethlehem, Pennsylvania 18017, United States
  • GSK Investigational Site
    Uniontown, Pennsylvania 15401, United States
  • GSK Investigational Site
    Knoxville, Tennessee 37923, United States
  • GSK Investigational Site
    Corsicana, Texas 75110, United States
  • GSK Investigational Site
    San Antonio, Texas 78229, United States
  • GSK Investigational Site
    Temple, Texas 76508, United States
  • GSK Investigational Site
    Salt Lake City, Utah 84112, United States
  • GSK Investigational Site
    Liverpool, New South Wales 2170, Australia
  • GSK Investigational Site
    Westmead, New South Wales 2145, Australia
  • GSK Investigational Site
    Adelaide, South Australia 5000, Australia
  • GSK Investigational Site
    Nedlands, Western Australia 6009, Australia
  • GSK Investigational Site
    Edmonton, Alberta T6G 2B7, Canada
  • GSK Investigational Site
    Brampton, Ontario L6T 0G1, Canada
  • GSK Investigational Site
    Kitchener, Ontario N2G 1E8, Canada
  • GSK Investigational Site
    London, Ontario N6A 5A5, Canada
  • GSK Investigational Site
    Mississauga, Ontario L5M 2V8, Canada
  • GSK Investigational Site
    Sudbury, Ontario P3E 5J1, Canada
  • GSK Investigational Site
    Montreal, Quebec H1T 2M4, Canada
  • GSK Investigational Site
    Pointe-Claire, Quebec H9R 4S3, Canada
  • GSK Investigational Site
    Cheb, 350 02, Czechia
  • GSK Investigational Site
    Liberec, 460 63, Czechia
  • GSK Investigational Site
    Louny, 440 01, Czechia
  • GSK Investigational Site
    Marianske Lazne, 353 01, Czechia
  • GSK Investigational Site
    Most, 434 64, Czechia
  • GSK Investigational Site
    Praha 10, 100 34, Czechia
  • GSK Investigational Site
    Praha 2, 128 08, Czechia
  • GSK Investigational Site
    Praha 4, 142 00, Czechia
  • GSK Investigational Site
    Sokolov, 356 01, Czechia
  • GSK Investigational Site
    Odense C, 5000, Denmark
  • GSK Investigational Site
    Roskilde, DK-4000, Denmark
  • GSK Investigational Site
    Amiens cedex 1, 80054, France
  • GSK Investigational Site
    Bordeaux, 33000, France
  • GSK Investigational Site
    Caen Cedex 9, 14033, France
  • GSK Investigational Site
    Créteil Cedex, 94010, France
  • GSK Investigational Site
    Lyon Cedex 03, 69437, France
  • GSK Investigational Site
    Paris Cedex 15, 75743, France
  • GSK Investigational Site
    Sainte Foy-Lès-Lyon, 69110, France
  • GSK Investigational Site
    Mannheim, Baden-Wuerttemberg 68167, Germany
  • GSK Investigational Site
    Ulm, Baden-Wuerttemberg 89081, Germany
  • GSK Investigational Site
    Muenchen, Bayern 81675, Germany
  • GSK Investigational Site
    Demmin, Mecklenburg-Vorpommern 17109, Germany
  • GSK Investigational Site
    Duesseldorf, Nordrhein-Westfalen 40210, Germany
  • GSK Investigational Site
    Leipzig, Sachsen 04129, Germany
  • GSK Investigational Site
    Berlin, 12053, Germany
  • GSK Investigational Site
    Hamburg, 22297, Germany
  • GSK Investigational Site
    Budapest, 1036, Hungary
  • GSK Investigational Site
    Budapest, 1097, Hungary
  • GSK Investigational Site
    Budapest, 1115, Hungary
  • GSK Investigational Site
    Budapest, 1135, Hungary
  • GSK Investigational Site
    Székesfehérvár, 8000, Hungary
  • GSK Investigational Site
    Aichi, 455-8530, Japan
  • GSK Investigational Site
    Gifu, 500-8717, Japan
  • GSK Investigational Site
    Gunma, 370-0001, Japan
  • GSK Investigational Site
    Ibaraki, 302-0014, Japan
  • GSK Investigational Site
    Ibaraki, 302-0022, Japan
  • GSK Investigational Site
    Kanagawa, 210-0852, Japan
  • GSK Investigational Site
    Kyoto, 604-8845, Japan
  • GSK Investigational Site
    Nagano, 388-8004, Japan
  • GSK Investigational Site
    Osaka, 558-8558, Japan
  • GSK Investigational Site
    Shiga, 523-0082, Japan
  • GSK Investigational Site
    Anyang-Si Gyeonggi-do, 431-070, Korea, Republic of
  • GSK Investigational Site
    Daegu, 700-721, Korea, Republic of
  • GSK Investigational Site
    Daejeon, 301-721, Korea, Republic of
  • GSK Investigational Site
    Gwangju, 501-757, Korea, Republic of
  • GSK Investigational Site
    Krakow, 31-501, Poland
  • GSK Investigational Site
    Lublin, 20-081, Poland
  • GSK Investigational Site
    Tarnow, 33-100, Poland
  • GSK Investigational Site
    Warszawa, 02-507, Poland
  • GSK Investigational Site
    Zabrze, 41-800, Poland
  • GSK Investigational Site
    Izhevsk, 426063, Russian Federation
  • GSK Investigational Site
    Kaluga, 248007, Russian Federation
  • GSK Investigational Site
    Khantymansiysk, 628012, Russian Federation
  • GSK Investigational Site
    Krasnodar, 350029, Russian Federation
  • GSK Investigational Site
    Krasnoyarsk, 660062, Russian Federation
  • GSK Investigational Site
    Moscow, 119121, Russian Federation
  • GSK Investigational Site
    Moscow, 125101, Russian Federation
  • GSK Investigational Site
    St-Petersburg, 197110, Russian Federation
  • GSK Investigational Site
    Ulyanovsk, 432063, Russian Federation
  • GSK Investigational Site
    Yaroslavl, 150062, Russian Federation
  • GSK Investigational Site
    Alcala de Henares, 28805, Spain
  • GSK Investigational Site
    Badalona, 08916, Spain
  • GSK Investigational Site
    Barcelona, 08011, Spain

Showing the first 100 of 123 sites across 15 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Natale P, Palmer SC, Jaure A, Hodson EM, Ruospo M, Cooper TE, Hahn D, Saglimbene VM, Craig JC, Strippoli GF. Hypoxia-inducible factor stabilisers for the anaemia of chronic kidney disease. Cochrane Database Syst Rev. 2022 Aug 25;8(8):CD013751. doi: 10.1002/14651858.CD013751.pub2. PubMed 36005278 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2013, a primary completion of May 2015 and a completion of Jun 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2016, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 24, 2013
First posted
Nov 6, 2013
Start
Oct 31, 2013
Primary completionActual
May 1, 2015
CompletionActual
Jun 15, 2015
Results first posted
Jun 6, 2016
Last update
Oct 12, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 12, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01977573
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Nov 6, 2013
Start date
Oct 31, 2013
Primary completion
May 1, 2015
Completion
Jun 15, 2015
Results posted
Jun 6, 2016
Last update
Oct 12, 2018

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: GSK1278863

Start the discussion